Prakt. lékáren. 2020; 16(4): 3-12 [Klin Farmakol Farm. 2020;34(2):84-88]

New direct oral anticoagulances - new molecules in research

Anna Zatloukalová
Lékařská fakulta, Centrum epidemiologického výzkumu, Ostravská univerzita
Univerzita Palackého Olomouc, Fakulta zdravotnických věd, Univerzita Palackého Olomouc
Ústav zdravotnického managementu, Univerzita Palackého Olomouc

Currently, new direct oral anticoagulants (DOAC) are gradually replacing the historically most frequently used warfarin. These are two classes of drugs directly inhibiting factor Xa (Xarelto, Eliquis, Lixiana) and thrombin (Pradaxa). It offers many positives that patients themselves will appreciate. These include, in particular, no need for regular monitoring, minimal drug and food interactions, or afavorable safety profile. However, one of the drawbacks is the absence of antidotes for overdose. Only Pradaxa currently has its specific antidote - Idarucizumab. Others are in development as well as new molecules of anticoagulants themselves.

Keywords: anticoagulants, antidotes, coagulation factors, betrixaban, otamixaban.

Published: January 5, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zatloukalová A. New direct oral anticoagulances - new molecules in research. Praktické lékárenství. 2020;16(4):3-12.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Burdová K. Přímá perorální antikogulancia. Klin Farmakol Farm. 2015, 29(4): 138-143.
    2. Zatloukalová A, Janoutová J, Homza M, Janout V. Epidemiologická studie nových perorálních antikoagulancií. Klin Farmakol Farm. 2018, 32(2), 3-7. Go to original source...
    3. Kvasnička J, Penka M, Kvasnička T, a kol. Doporučení české společnosti pro trombózu a hemostázu České lékařské společnosti J. E. Purkyně pro bezpečnou léčbu novými perorálními antikoagulancii (NOAC) - dabigatran exilátem, apixabanem a rivaroxabanem. Vnitř. Lék. 2015; 61(6): 537-546.
    4. Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine [online]. 2019 [cit. 2019-03-26]. DOI: 10.1056/NEJMoa1814051. ISSN 0028-4793. Dostupné z: http://www.nejm.org/doi/10.1056/NEJMoa1814051 Go to original source... Go to PubMed...
    5. Karetová D, Bultas J. Řešení urgentních stavů spojených s rizikem krvácení u nemocných užívajících nová perorální antikoagulancia - možnosti ukončení účinku. Remedia. 26(2): 235-140.
    6. Ramacciotti E, Hoppensteadt D, Fareed J. Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population?. Clinical and Applied Thrombosis/Hemostasis [online]. 2016, 23(7), 701-702 [cit. 2019-02-25]. DOI: 10.1177/1076029616683805. ISSN 1076-0296. Dostupné z: http://journals.sagepub.com/doi/10.1177/1076029616683805 Go to original source... Go to PubMed...
    7. Skelley J, Thomason A, Nolen J. Betrixaban (Bevyxxa): A Direct‑Acting Oral Anticoagulant Factor Xa Inhibitor. P & T : a peer‑reviewed journal for formulary management [online]. 2018, 43(2), 85-120 [cit. 2019-02-25]. Dostupné z: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768296/
    8. Dobesh PP, Trevarrow BJ. Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis. The American Journal of Medicine [online]. 2018 [cit. 2019-02-25]. DOI: 10.1016/j.amjmed.2018. 08. 024. ISSN 00029343. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S0002934318308520 Go to original source...
    9. Lekura J, Kalus JS. Overview of betrixaban and its role in clinical practice. American Journal of Health‑System Pharmacy[online]. 2018, 75(15), 1095-1102 [cit. 2019-02-25]. DOI: 10.2146/ajhp170785. ISSN 1079-2082. Dostupné z: https://academic.oup.com/ajhp/article/75/15/1095/5102024 Go to original source... Go to PubMed...
    10. Beyer‑Westendorf J, Verhamme P, Bauersachs R. Betrixaban for prevention of venous thromboembolism in acute medically ill patients. European Heart Journal Supplements [online]. 2018, 20(suppl E), E16-E22 [cit. 2019-02-25]. DOI: 10.1093/eurheartj/suy017. ISSN 1520-765X. Dostupné z: https://academic.oup.com/eurheartjsupp/article/20/suppl_E/E16/4993363 Go to original source... Go to PubMed...
    11. Iwatsuki Y, Sato T, Moritani Y, Shigenaga T, et al. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. European Journal of Pharmacology[online]. 2011, 673(1-3), 49-55 [cit. 2019-03-19]. DOI: 10.1016/j.ejphar.2011. 10. 009. ISSN 00142999. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S0014299911012398 Go to original source... Go to PubMed...
    12. Kaku S, Suzuki M, Saitoh M, Funatsu T, et al. Darexaban: Anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti‑inhibitor coagulant complex and recombinant factor VIIa. Thrombosis Research [online]. 2013, 131(5), 450-456 [cit. 2019-03-19]. DOI: 10.1016/j.thromres.2013. 03. 016. ISSN 00493848. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S0049384813001035 Go to original source... Go to PubMed...
    13. Kadokura T, Kashiwa M, Groenendaal D, Heeringa M, et al. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. Biopharmaceutics & Drug Disposition [online]. 2013, 34(8), 431-441 [cit. 2019-03-19]. DOI: 10.1002/bdd.1858. ISSN 01422782. Dostupné z: http://doi.wiley.com/10.1002/bdd.1858 Go to original source... Go to PubMed...
    14. Hashimoto T, Suzuki K, Kihara Y, et al. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica [online]. 2012, 43(6), 534-547 [cit. 2019-03-19]. DOI: 10.3109/00498254.2012.738045. ISSN 0049-8254. Dostupné z: http://www.tandfonline.com/doi/full/10.3109/00498254.2012.738045 Go to original source... Go to PubMed...
    15. Kadokura T, Groenendaal D, Heeringa M, Mol R, et al. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. European Journal of Drug Metabolism and Pharmacokinetics [online]. 2014, 39(1), 1-9 [cit. 2019-03-19]. DOI: 10.1007/s13318-013-0141-1. ISSN 0378-7966. Dostupné z: http://link.springer.com/10.1007/s13318-013-0141-1 Go to original source... Go to PubMed...
    16. Kadokura T, Taniuchi Y, Inoue H, Saito M, et al. Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects. Int. Journal of Clinical Pharmacology and Therapeutics [online]. 2013, 51(03), 200-206 [cit. 2019-03-19]. DOI: 10.5414/CP201804. ISSN 0946-1965. Dostupné z: http://www.dustri.com/article_response_page.html?artId=10188 & doi=10.5414/CP201804 & L=0 Go to original source... Go to PubMed...
    17. Eriksson B I, Turpie AGG, Lassen MR, et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). Journal of Thrombosis and Haemostasis [online]. 2010, 8(4), 714-721 [cit. 2019-03-20]. DOI: 10.1111/j.1538-7836.2010.03748.x. ISSN 15387933. Dostupné z: http://doi.wiley.com/10.1111/j.1538-7836.2010.03748.x Go to original source... Go to PubMed...
    18. Steg Ph.G, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double‑blind, placebo‑controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. European Heart Journal [online]. 2011, 32(20), 2541-2554 [cit. 2019-03-20]. DOI: 10.1093/eurheartj/ehr334. ISSN 0195-668X. Dostupné z: https://academic.oup.com/eurheartj/article‑lookup/doi/10.1093/eurheartj/ehr334 Go to original source... Go to PubMed...
    19. Sakon M, Nakamura M. Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis‑controlled, open‑label study. Thrombosis Research [online]. 2012, 130(3), e52-e59 [cit. 2019-03-20]. DOI: 10.1016/j.thromres.2012. 06. 009. ISSN 00493848. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S0049384812002800 Go to original source... Go to PubMed...
    20. Gómez‑Outes A, Suárez‑Gea ML, Lecumberri R, Rocha E, at al. New parenteral anticoagulants in development. Therapeutic Advances in Cardiovascular Disease[online]. 2011, 5(1), 33-59 [cit. 2019-03-25]. DOI: 10.1177/1753944710387808. ISSN 1753-9447. Dostupné z: http://journals.sagepub.com/doi/10.1177/1753944710387808 Go to original source... Go to PubMed...
    21. Hinder M, Frick A, Jordaan P, Hesse G, et al. Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clinical Pharmacology & Therapeutics[online]. 2006, 80(6), 691-702 [cit. 2019-03-25]. DOI: 10.1016/j.clpt.2006. 09. 002. ISSN 00099236. Dostupné z: http://doi.wiley.com/10.1016/j.clpt.2006. 09. 002 Go to original source...
    22. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, Double‑Blind, Dose‑Ranging Study of Otamixaban, a Novel, Parenteral, Short‑Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. Circulation [online]. 2007, 115(20), 2642-2651 [cit. 2019-03-25]. DOI: 10.1161/CIRCULATIONAHA.106.653428. ISSN 0009-7322. Dostupné z: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.106.653428 Go to original source... Go to PubMed...
    23. Sabatine MS, EM Antman, Widimsky P, et al. Otamixaban for the treatment of patients with non‑ST‑elevation acute coronary syndromes (SEPIA‑ACS1 TIMI 42): a randomised, double‑blind, active‑controlled, phase 2 trial. The Lancet [online]. 2009, 374(9692), 787-795 [cit. 2019-03-25]. DOI: 10.1016/S0140-6736(09)61454-9. ISSN 01406736. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S0140673609614549 Go to original source... Go to PubMed...
    24. Dillinger J‑G, Gregory DUCROCQ, Elbez Y, et al. Activated Clotting Time to Guide Heparin Dosing in Non-ST‑Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. Circulation: Cardiovascular Interventions [online]. 2018, 11(6) [cit. 2019-03-26]. DOI: 10.1161/CIRCINTERVENTIONS.118.006084. ISSN 1941-7640. Dostupné z: https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.118.006084 Go to original source... Go to PubMed...
    25. Deharo P, Ducrocq G, Bode CH, et al. Timing of Angiography and Outcomes in High‑Risk Patients With Non-ST‑Segment-Elevation Myocardial Infarction Managed Invasively. Circulation [online]. 2017, 136(20), 1895-1907 [cit. 2019-03-26]. DOI: 10.1161/CIRCULATIONAHA.117.029779. ISSN 0009-7322. Dostupné z: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029779 Go to original source... Go to PubMed...
    26. Steg PG. Anticoagulation With Otamixaban and Ischemic Events in Non-ST‑Segment Elevation Acute Coronary Syndromes. JAMA [online]. 2013, 310(11) [cit. 2019-03-26]. DOI: 10.1001/jama.2013.277165. ISSN 0098-7484. Dostupné z: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.277165 Go to original source... Go to PubMed...
    27. Dhakal P. Rayamajhi S, Verma V, Gundabolu K, Bhatt VR. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. Clinical and Applied Thrombosis/Hemostasis [online]. 2016, 23(5), 410-415 [cit. 2019-03-27]. DOI: 10.1177/1076029616675970. ISSN 1076-0296. Dostupné z: http://journals.sagepub.com/doi/10.1177/1076029616675970 Go to original source... Go to PubMed...
    28. Levy JH, Douketis J, Weitz JI. Reversal agents for non‑vitamin K antagonist oral anticoagulants. Nature Reviews Cardiology [online]. 2018, 15(5), 273-281 [cit. 2019-03-27]. DOI: 10.1038/nrcardio.2017.223. ISSN 1759-5002. Dostupné z: http://www.nature.com/doifinder/10.1038/nrcardio.2017.223 Go to original source... Go to PubMed...
    29. Crowther M, Cuker A. How can we reverse bleeding in patients on direct oral anticoagulants? Kardiologia Polska [online]. 2019, 77(1), 3-11 [cit. 2019-03-27]. DOI: 10.5603/KP.a2018.0197. ISSN 1897-4279. Dostupné z: https://ojs.kardiologiapolska.pl/kp/article/view/12634 Go to original source... Go to PubMed...
    30. Ansell JE, Bakhru SH, Laulicht BE, et al. Single‑dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thrombosis and Haemostasis [online]. 2017, 117(02), 238-245 [cit. 2019-03-27]. DOI: 10.1160/TH16-03-0224. ISSN 0340-6245. Dostupné z: http://www.thieme‑connect.de/DOI/DOI?10.1160/TH16-03-0224 Go to original source... Go to PubMed...
    31. Dabi A, Koutrouvelis AP. Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications. Critical Care Research and Practice [online]. 2018, 2018, 1-11 [cit. 2019-03-27]. DOI: 10.1155/2018/4907164. ISSN 2090-1305. Dostupné z: https://www.hindawi.com/journals/ccrp/2018/4907164/ Go to original source... Go to PubMed...
    32. Riley TR, Gauthier‑Lewis ML, Sanchez CHK, DOUGLAS JS. Role of agents for reversing the effects of target‑specific oral anticoagulants. American Journal of Health‑System Pharmacy [online]. 2017, 74(2), 54-61 [cit. 2019-03-27]. DOI: 10.2146/ajhp150810. ISSN 1079-2082. Dostupné z: https://academic.oup.com/ajhp/article/74/2/54/5102888 Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.